A portion of the US holdings for this investor are reported in this report and a portion are reported by other reporting manager(s). The Form 13F report requires disclosure of the manager that files the report, the name and class of the security, the CUSIP code, the number of shares as
of the end of the calendar quarter for which the report is filed, and the total market value. The market value
column should not be used as a substitute for Assets Under Management (AUM), as it does not include cash held in
accounts.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
Person Signing this Report on Behalf of Reporting Manager:
Name
Title
City, State
Date
Brent M. Faduski
Officer
Boston, Massachusetts
8/12/2022
The filing of this report shall not be deemed an admission, for purposes of Section 13(t), 13(d), 13(g), or 16(a) under the Securities Exchange Act of 1934, as amended, and the rules thereunder, or for any other purpose, that the Reporting Manager or any other person (including Other Managers or Other Included Managers named herein) is the beneficial owner of any securities. SV Health Investors, LLC, a Delaware limited liability company ("Investors"), is an institutional investment manager subject to Section 13(f) of the Securities Exchange Act of 1934 and the rules promulgated thereunder. SV Life Sciences Fund IV, L.P. ("SVLS IV LP") and SV Life Sciences Fund IV Strategic Partners, L.P. ("Strategic Partners IV" and together with SVLS IV LP, the "Fund IV Entities"), and SV Life Sciences Fund V, L.P. ("SVLS V LP") and SV Life Sciences Fund V Strategic Partners, L.P. ("Strategic Partners V" and together with SVLS V LP, the "Fund V Entities"), and SV Life Sciences Fund VI, L.P. ("SVLS VI LP") and SV Life Sciences Fund VI Strategic Partners, L.P. ("Strategic Partners VI" and together with SVLS VI LP, the "Fund VI Entities"), and International Life Sciences Fund III (LP1), L.P. ("ILSF III LPI') and International Life Sciences Fund III Co-Investment, L.P. ("ILSF Co-Invest') and International Life Sciences Fund III Strategic Partners, L.P. ("ILSF Strategic Partners' and together with ILSF III LPI and ILSF Co-Invest, the "ILSF Entities'), which are each Delaware limited partnerships (the Fund IV Entities, the Fund V Entities, the Fund VI Entities and the ILSF Entities together, the "Funds"), directly own certain security positions reported by Investors, which is the investment adviser of the Funds. SV Life Sciences Fund VI (GP), L.P., a Delaware limited partnership ("SVLS VI GP") is the general partner of the Fund VI Entities, and SVLSF VI, LLC, a Delaware limited liability company is the general partner of SVLS VI GP. Certain of the security positions reported by Investors are also being reported by SVLS VI GP and SVLSF VI, LLC (together, the "GPs"). Each of SVLS VI GP, SVLSF VI, LLC and Investors may be deemed to share voting power and control over the shares held by the Fund VI Entities. Investors may also be deemed to share voting power and control over the shares held by the Fund IV Entities, the Fund V Entities and the ILSF Entities. Each of the GPs and Investors disclaims beneficial ownership of the shares held by the Funds, except to the extent of any pecuniary interest therein.
List of Other Managers Reporting for SV Health Investors, LLC:
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.